Dr. Michael Rosenblum

Dr. Rosenblum received his medical degree and PhD from the Medical College of Wisconsin. Subsequently, he completed his dermatology residency training at UCSF in the prestigious Physician-Scientist Training Pathway. He joined the UCSF faculty in 2012 and since that time has become one of the world's leading skin immunologists. Dr. Rosenblum is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists, the NIH Director＇s New Innovator Award, the Dermatology Foundation＇s Charles & Daneen Stiefel Scholar Award in Autoimmune & Connective Tissue Diseases, as well as multiple NIH R01 & R21 awards. Dr. Rosenblum was named the William Montagna Lecturer by the Society for Investigative Dermatology. He was the scientific co-founder of Delinia Bio., which was acquired by Celgene in 2017. Dr. Rosenblum is also a co-founder of TRex Bio., Radera Bio., and Sitryx Bio. He is currently the Senior Associate Vice Chair of Research for the UCSF Department of Dermatology and has authored over 100 basic science research papers.